The Antibacterial and Antibiofilm Activities of Resveratrol on Gram-positive and Gram-negative Bacteria

Abstract

Aim: Resveratrol (3,5,4’-trihydroxystilbene) shows antimicrobial activity against many pathogens. It has been detected that subinhibitory concentrations can reduce bacterial motility and interference with quorum sensing, lead to reduced bacterial toxin production, and inhibit biofilm formation. In this study, we aimed to investigate resveratrol’s antibacterial and antibiofilm activities on some Gram-positive and Gram-negative bacteria. Material and Method: The bacterial strains, including Staphylococcus aureus (ATCC-29213), Bacillus subtilis (ATCC- 6051), Escherichia coli (ATCC-25923), and Pseudomonas aeruginosa (ATCC-27853) were grown overnight in LB broth at 37°C in a humidified chamber. The resveratrol was dissolved in 1.5% of dimethyl sulfoxide (DMSO). Serial two-fold dilutions of the resveratrol, ranging from 16 to 0.5 mg/ml, were prepared in a 96-well plate. The microdilution method determined the minimum inhibitory concentration (MIC) for the resveratrol. Bacterial biofilm formation was assessed using the crystal violet assay. The agar gel diffusion assay was also performed to determine the antimicrobial activity. Results: In these assays, the resveratrol inhibited the growth of both Gram-positive and Gram-negative bacteria strains tested, with inhibition zone diameters ranging from 19.8 to 22 mm and MIC values of 4 mg/ml, confirming its antimicrobial properties. Concerning the effect of resveratrol on biofilm formation, an inhibition ranging from 24% to 99% on the total biofilm mass was achieved for all bacteria strains (Fig. 2 and Fig. 3). 16 mg/ml of resveratrol is the most effective dose for antibiofilm activity. Conclusion: Resveratrol has gained significant scientific and public attention not only for being a possible natural antimicrobial but also for its potential functional and therapeutic applications. Further studies should be planned to understand the molecular mechanism underlying resveratrol’s inhibitory effect, investigate the synergistic effects of resveratrol with antibiotics, and apply it in clinical practice.

Keywords

• antibacterial activity
• antibiofilm activity
• minimal inhibitory concentration
• resveratrol; gel diffusion

References

1. 1. Herrera D, Alonso B, Leon R, Roldan S, Sanz M. Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm. J Clin Periodontol. 2008;35(8 Suppl):45–66.
2. 2. Kouidhi B, Al Qurashi YM, Chaieb K. Drug resistance of bacterial dental biofilm and the potential use of natural compounds as alternative for prevention and treatment. Microb Pathog. 2015;80:39–49.
3. 3. Sun M, Zhou Z, Dong J, Zhang J, Xia Y, Shu R. Antibacterial and antibiofilm activities of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) against periodontopathic bacteria. Microb Pathog. 2016;99:196–203.
4. 4. Herrera Herrera A, Franco Ospina L, Fang L, Diaz Caballero A. Susceptibility of Porphyromonas gingivalis and Streptococcus mutans to Antibacterial Effect from Mammea americana. Adv Pharmacol Sci. 2014;2014:384815.
5. 5. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783–840.
6. 6. Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French paradox revisited. Front Pharmacol. 2012;3:141.
7. 7. Marques FZ, Markus MA, Morris BJ. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol. 2009;41(11):2125–8.
8. 8. Neves AR, Lucio M, Lima JL, Reis S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drugdelivery, and membrane interactions. Curr Med Chem. 2012;19(11):1663–81.

9. 9. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339(8808):1523–6.
10. 10. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, TomasBarberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013;19(34):6064–93.
11. 11. Vestergaard M, Ingmer H. Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents. 2019;53(6):716–23.
12. 12. Vidavalur R, Otani H, Singal PK, Maulik N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol. 2006;11(3):217–25.
13. 13. Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol. 2006;4(8):629–36.
14. 14. Dadi PK, Ahmad M, Ahmad Z. Inhibition of ATPase activity of Escherichia coli ATP synthase by polyphenols. Int J Biol Macromol. 2009;45(1):72–9.
15. 15. Lee K, Lee JH, Ryu SY, Cho MH, Lee J. Stilbenes reduce Staphylococcus aureus hemolysis, biofilm formation, and virulence. Foodborne Pathog Dis. 2014;11(9):710–7.
16. 16. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3(2):16375.
17. 17. Tang M, Wei X, Wan X, Ding Z, Ding Y, Liu J. The role and relationship with efflux pump of biofilm formation in Klebsiella pneumoniae. Microb Pathog. 2020;147:104244.
18. 18. https://www.eucast.org/ast_of_bacteria/mic_determination/?no_ cache=1. Accessed 03.03.2022, 2022.
19. 19. Schillaci D, Cusimano M, Russo D, Arizza V. Antimicrobial peptides from echinoderms as antibiofilm agents: a natural strategy to combat bacterial infections. Italian Journal of Zoology 2014;81:312–21.
20. 20. Abedini E, Khodadadi E, Zeinalzadeh E, et al. A Comprehensive Study on the Antimicrobial Properties of Resveratrol as an Alternative Therapy. Evidence-Based Complementary and Alternative Medicine. 2021.
21. 21. Paulo L, Ferreira S, Gallardo E, Queiroz JA, Domingues F. Antimicrobial activity and effects of resveratrol on human pathogenic bacteria. World Journal of Microbiology and Biotechnology. 2010;26:1533–8.
22. 22. Lechner D, Gibbons S, Bucar F. Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis. Joubrla of Antimicrobials and Chemotheraphy. 2008;62:345–8. Kafkas J Med Sci 2022; 12(3):201–206206
23. 23. Sun D, Hurdle JG, Lee R, Lee R, Cushman M, Pezzuto JM. Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead. ChemMedChem. 2012;7(9):1541–5.
24. 24. Augustine N, Goel AK, Sivakumar KC, Kumar RA, Thomas S. Resveratrol--a potential inhibitor of biofilm formation in Vibrio cholerae. Phytomedicine. 2014;21(3):286–9.
25. 25. Docherty JJ, Fu MM, Tsai M. Resveratrol selectively inhibits Neisseria gonorrhoeae and Neisseria meningitidis. J Antimicrob Chemother. 2001;47(2):243–4.
26. 26. Ferreira S, Silva F, Queiroz JA, Oleastro M, Domingues FC. Resveratrol against Arcobacter butzleri and Arcobacter cryaerophilus: activity and effect on cellular functions. Int J Food Microbiol. 2014;180:62–8.
27. 27. Jung CM, Heinze TM, Schnackenberg LK, et al. Interaction of dietary resveratrol with animal-associated bacteria. FEMS Microbiol Lett. 2009;297(2):266–73.
28. 28. Mahady GB, Pendland SL. Resveratrol inhibits the growth of Helicobacter pylori in vitro. Am J Gastroenterol. 2000;95(7):1849.
29. 29. Singkham-In U, Higgins PG, Wannigama DL, Hongsing P, Chatsuwan T. Rescued chlorhexidine activity by resveratrol against carbapenem-resistant Acinetobacter baumannii via down-regulation of AdeB efflux pump. PLoS One. 2020;15(12):e0243082.
30. 30. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents. 1999;11(3-4):217–21; discussion 237–19.
31. 31. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95–108.
32. 32. He Z, Huang Z, Zhou W, Tang Z, Ma R, Liang J. Anti-biofilm Activities from Resveratrol against Fusobacterium nucleatum. Front Microbiol. 2016;7:1065.
33. 33. Coenye T, Brackman G, Rigole P, et al. Eradication of Propionibacterium acnes biofilms by plant extracts and putative identification of icariin, resveratrol and salidroside as active compounds. Phytomedicine. 2012;19(5):409–12.
34. 34. Qin N, Tan X, Jiao Y, et al. RNA-Seq-based transcriptome analysis of methicillin-resistant Staphylococcus aureus biofilm inhibition by ursolic acid and resveratrol. Sci Rep. 2014;4:5467.
35. 35. Lee JH, Cho HS, Joo SW, et al. Diverse plant extracts and trans-resveratrol inhibit biofilm formation and swarming of Escherichia coli O157:H7. Biofouling. 2013;29(10):1189203.